Latest Oncology News

Niraparib Plus Dostarlimab Misses the Mark in Platinum-Resistant Ovarian Cancer

Niraparib Plus Dostarlimab Misses the Mark in Platinum-Resistant Ovarian Cancer

June 25th 2022

Kristi Rosa

The combination of niraparib and dostarlimab produced a low overall response rate in patients with platinum-resistant ovarian cancer without a known BRCA mutation who had progressed and received prior bevacizumab, one that did not reach the threshold for second-stage accrual to the phase 2 MOONSTONE/GOG-3032 trial.

FDA Approves Liso-cel for Second-Line Relapsed/Refractory LBCL

FDA Approves Liso-cel for Second-Line Relapsed/Refractory LBCL

June 24th 2022

Caroline Seymour

The FDA has approved lisocabtagene maraleucel as second-line therapy for adult patients with large B-cell lymphoma, including diffuse large B-cell lymphoma not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.

Amivantamab/Lazertinib Combo Demonstrates Durable Activity in EGFR-Mutated NSCLC

Amivantamab/Lazertinib Combo Demonstrates Durable Activity in EGFR-Mutated NSCLC

June 24th 2022

Kristi Rosa

The combination of amivantamab-vmjw and lazertinib produced encouraging responses with acceptable safety in patients with EGFR-mutated non–small cell lung cancer who expressed on osimertinib and platinum-based chemotherapy.

Wenham Discusses the Growing Treatment Landscape Across Gynecologic Cancers

Wenham Discusses the Growing Treatment Landscape Across Gynecologic Cancers

June 24th 2022

Ryan Scott

Robert Wenham, MD, MS, FACOG, FACS, discusses the current treatment landscape for patients with cervical and endometrial cancers, ADCs and PARP inhibitors in ovarian cancer, advancements in HER2-positive breast cancer, and surgical options for patients with ovarian cancer.

Tamibarotene Highlights Novel Treatment Strategy in RARA+ AML

Tamibarotene Highlights Novel Treatment Strategy in RARA+ AML

June 24th 2022

Kyle Doherty

Retinoic acid receptor α, a gene overexpressed in approximately 30% of unfit patients with newly diagnosed acute myeloid leukemia, has emerged as a potential therapeutic target.

Latest Oncology Videos

All Oncology News

Patient Profile 3: 43-Year-Old Woman With Metastatic Breast Cancer Progressing Through Multiple Lines of Therapy

June 8th 2022

Shanu Modi, MD

Expert oncologist Rena Callahan, MD, shares a real-world clinical scenario of a 43-year-old woman with metastatic breast cancer who progressed through multiple lines of therapy.

Nivolumab + Ipilimumab Combination Regimen for Advanced RCC

June 8th 2022

Robert S. Alter, MD

Oncologists review the IO/IO combination regimens available for treatment of advanced RCC and discuss patient selection for treatment with nivolumab and ipilimumab.

Tucatinib Plus First-Line Maintenance Under Exploration in Metastatic HER2+ Breast Cancer

June 8th 2022

Ariana Pelosci

Tucatinib plus first-line standard-of-care maintenance therapy with trastuzumab and pertuzumab is being investigated for its ability to improve progression-free survival and maintain health-related quality of life in patients with HER2-positive metastatic breast cancer.

Patient Profile 2: Treatment Sequencing in a Patient with Progressive Brain Metastases

June 8th 2022

Shanu Modi, MD

Expert perspectives on use of trastuzumab deruxtecan in patients with HER2+ breast cancer who develop brain metastases.

Clinical Trials in HER2+ mBC: DESTINY-Breast03 and HER2CLIMB

June 8th 2022

Joyce A. O'Shaughnessy, MD

Highlights of the results from the DESTINY-Breast03 and HER2CLIMB trials, evaluating T-DXd and tucatinib, respectively, in HER2+ metastatic breast cancer.

Patient Profile Presentation: A 70-Year-Old Man with Stage 4 Clear Cell RCC

June 8th 2022

Robert S. Alter, MD

Dr Elan Diamond presents the patient profile of a 70-year-old man with stage IV clear cell renal cell carcinoma.

Dostarlimab Demonstrates Promising Response Rates in Advanced, Recurrent Endometrial Cancer

June 8th 2022

Kristie L. Kahl

Single-agent dostarlimab generated durable antitumor activity in patients with advanced or recurrent endometrial cancer with mismatch repair deficient/microsatellite instability–high or mismatch repair proficient/mismatch stable disease.

Asciminib Represents New Standard of Care for Patients With CML in Chronic Phase

June 7th 2022

Brittany Lovely

Asciminib continued to demonstrate durable, major molecular responses as well as a tolerable safety profile vs bosutinib suggesting a long-term benefit in adult patients with chronic myelogenous leukemia in chronic phase who have been previously treated with 2 tyrosine kinase inhibitors.

Dr. Velcheti on the Safety of Nemvaleukin in Solid Tumors

June 7th 2022

Vamsidhar Velcheti, MD

Vamsidhar Velcheti, MD, discusses the safety of nemvaleukin alfa in patients with advanced solid tumors in the phase 1/2 ARTISTRY-1 trial.

Larotrectinib Elicits OS Benefit Vs SOC in TRK Fusion–Positive Tumors

June 7th 2022

Conor Killmurray

Larotrectinib demonstrated longer overall survival compared with standard-of-care therapy in patients with TRK fusion–positive cancer.

Cobimetinib/Vemurafenib Combo Showcases Antitumor Activity in BRAF-Mutated Solid Tumors

June 7th 2022

Kristie L. Kahl

A combination comprised of cobimetinib and vemurafenib demonstrated evidence of antitumor activity in patents with advanced solid tumors harboring BRAF V600E and other mutations who are not otherwise eligible to receive other FDA-approved therapies.

Seribantumab Elicits Deep, Durable Responses in Solid Tumors Harboring NRG1 Fusions

June 7th 2022

Chris Ryan

Seribantumab was found to produce encouraging overall response rates with acceptable tolerability when used as a monotherapy in patients with solid tumors harboring NRG1 fusions.

Adagrasib Delivers Durable CNS-Specific Activity in KRAS G12C+ NSCLC

June 7th 2022

Dylann Cohn-Emery

Adagrasib led to an intracranial objective response rate of 32% and a median intracranial duration of response that was not reached in patients with KRAS G12C–mutant non–small cell lung cancer and active, untreated CNS metastases, according to findings from the KRYSTAL-1 trial.

Afatinib Efficacy and Safety to Be Investigated in Metastatic Solid Tumors With NRG1 Fusions

June 7th 2022

Ashling Wahner

Afatinib may prove effective and tolerable in patients with advanced or metastatic solid tumors with NRG1 gene fusions, according to the rationale for a prospective real-world outcomes study that was presented as a trial in progress at the 2022 ASCO Annual Meeting.

Selinexor Demonstrates PFS Benefit in Advanced Endometrial Cancer, Including p53 Wild-Type Tumors

June 7th 2022

Will Pizii

Selinexor generated a longer median progression-free survival compared with placebo in patients with advanced or recurrent endometrial cancer, including those with p53 wild-type tumors.

See All News